ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

EOLS vs OVID // FORWARD P/E MULTIPLE

Evolus Inc. (NASDAQ) VS. Ovid Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: EOLS 3 — OVID 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EOLS VS. OVID) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC EOLS OVID SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 66.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -28.50% -6.50 OVID /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -9.20% -7.67% -1.53 OVID /fcf-yield <GO>
Operating Margin -11.00% -60.00% +49.00 EOLS /operating-margins <GO>
Net Profit Margin -17.40% -60.00% +42.60 EOLS /net-margins <GO>
Revenue Growth (YoY) 11.60% 180.00% -168.40 OVID /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 11.46 -11.26 OVID /balance-sheet <GO>
Piotroski F-Score Quality 4/9 3/9 +1.00 EOLS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.1 56.1 -9.98 OVID /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $496.7M $500.0M -$3.3M OVID /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR EOLS REV OVID REV EOLS GROSS % OVID GROSS % EOLS FCF OVID FCF
FY 2025 $297.2M $7.3M 66.3% — -$45.7M -$38.3M
FY 2024 $266.3M $566.0K 68.5% — -$19.5M -$56.0M
FY 2023 $202.1M $392.0K — — -$34.0M -$45.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EOLS // BETA —
OVID // BETA —